COVID-19 is a disease with high rate of morbidity if symptomatic. There is a great need of
treatments to decrease the severity. The vast majority of patients needing intensive care are
men, and this may be due to the androgens, either by regulation of TMPRSS2, necessary for
virus internalization, or other mechanisms. Enzalutamide is an antiandrogen inhibiting the
expression of androgen regulated proteins, such as TMPRSS2. The aim of this trial is to
evaluate a possible beneficial effect of short-term enzalutamide treatment of COVID-19
patients.
Phase:
Phase 2
Details
Lead Sponsor:
Andreas Josefsson
Collaborators:
Astellas Pharma Europe Ltd. Göteborg University Helsingborgs Hospital Jonkoping County Hospital Norrlands University Hospital Sahlgrenska University Hospital, Sweden Skane University Hospital Sundsvall Hospital Umeå University University Hospital, Umeå Uppsala University Hospital